[go: up one dir, main page]

UY26514A1 - " composición para el tratamiento de tejidos danados". - Google Patents

" composición para el tratamiento de tejidos danados".

Info

Publication number
UY26514A1
UY26514A1 UY26514A UY26514A UY26514A1 UY 26514 A1 UY26514 A1 UY 26514A1 UY 26514 A UY26514 A UY 26514A UY 26514 A UY26514 A UY 26514A UY 26514 A1 UY26514 A1 UY 26514A1
Authority
UY
Uruguay
Prior art keywords
composition
damaged tissues
treatment
agent
wound
Prior art date
Application number
UY26514A
Other languages
English (en)
Inventor
Michael John Davies
Jonathan Paul Huggins
Fraser Stuart Mcinstosh
Nicholas Laurence Occleston
Fraser Stuart Mcintosh
Original Assignee
Pfizer
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer filed Critical Pfizer
Publication of UY26514A1 publication Critical patent/UY26514A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A61K38/1858—Platelet-derived growth factor [PDGF]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurology (AREA)
  • Urology & Nephrology (AREA)
  • Biomedical Technology (AREA)
  • Epidemiology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Neurosurgery (AREA)
  • Ophthalmology & Optometry (AREA)
  • Dermatology (AREA)
  • Hospice & Palliative Care (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Communicable Diseases (AREA)
  • Psychiatry (AREA)
  • Vascular Medicine (AREA)
  • Oncology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Virology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Cardiology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Se describe un agente farmacéutico para uso en el tratamiento (por ejemplo, curación) de tejidos danados, tal como una herida, comprendiendo el agente farmacéutico una composición que comprende: (a) un factor de crecimiento; (b) un agente inhibidor; y, opcionalmente, (c) un vehículo, diluyente o excipiente farmaceúticamente aceptable; pudiendo el agente inhibir la acción de al menos una proteína adversa específica (por ejemplo, una proteasa específica) que está regulada positivamente en un entorno de tejido danado, tal como una herida.
UY26514A 1999-12-29 2000-12-28 " composición para el tratamiento de tejidos danados". UY26514A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GBGB9930768.8A GB9930768D0 (en) 1999-12-29 1999-12-29 Composition

Publications (1)

Publication Number Publication Date
UY26514A1 true UY26514A1 (es) 2001-07-31

Family

ID=10867127

Family Applications (1)

Application Number Title Priority Date Filing Date
UY26514A UY26514A1 (es) 1999-12-29 2000-12-28 " composición para el tratamiento de tejidos danados".

Country Status (12)

Country Link
EP (1) EP1242120A2 (es)
JP (1) JP2003519193A (es)
AR (1) AR027122A1 (es)
AU (1) AU1878201A (es)
CA (1) CA2395487A1 (es)
CO (1) CO5271671A1 (es)
EC (1) ECSP003859A (es)
GB (1) GB9930768D0 (es)
GT (1) GT200000224A (es)
PE (1) PE20011095A1 (es)
UY (1) UY26514A1 (es)
WO (1) WO2001049309A2 (es)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7034132B2 (en) 2001-06-04 2006-04-25 Anderson David W Therapeutic polypeptides, nucleic acids encoding same, and methods of use
ES2304401T3 (es) * 2000-10-16 2008-10-16 Genentech, Inc. Metodos de tratamiento que utilizan polipeptidos wisp.
AU2002236768B2 (en) 2001-07-27 2006-06-08 The Board Of Regents, The University Of Texas System Use of thrombin-derived peptides for the therapy of chronic dermal ulcers
WO2003029819A1 (fr) * 2001-09-28 2003-04-10 Takeda Chemical Industries, Ltd. Procede pour le criblage preventif / le traitement des maladies d'os ou d'articulations
WO2004014937A2 (en) 2002-07-02 2004-02-19 The Board Of Regents, The University Of Texas System Thrombin peptide derivatives
CN1913917B (zh) 2003-12-31 2012-02-01 正统逻辑公司 凝血酶肽衍生物的药物组合物
CN101365715B (zh) 2005-10-07 2013-03-27 P·安杰莱蒂分子生物学研究所 基质金属蛋白酶11疫苗
JP5960944B2 (ja) * 2006-11-15 2016-08-02 コーダ セラピューティクス， インコーポレイテッド 創傷治癒のための改善された方法および組成物
KR101629504B1 (ko) * 2014-04-14 2016-06-10 주식회사 엘지생활건강 사이토카인 조합을 함유하는 피부 상태 개선용 조성물
US20200129561A1 (en) * 2017-04-21 2020-04-30 Intrexon Corporation Delivery of autologous cells comprising matrix metalloproteinase for treatment of scleroderma

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH01279840A (ja) * 1988-04-28 1989-11-10 Wakunaga Pharmaceut Co Ltd 新規外用組成物
GB9405076D0 (en) * 1994-03-16 1994-04-27 Inst Of Ophtalmology A medical use of matrix metalloproteinase inhibitors

Also Published As

Publication number Publication date
CA2395487A1 (en) 2001-07-12
GB9930768D0 (en) 2000-02-16
AR027122A1 (es) 2003-03-12
ECSP003859A (es) 2002-09-27
EP1242120A2 (en) 2002-09-25
WO2001049309A3 (en) 2002-02-28
PE20011095A1 (es) 2001-10-27
JP2003519193A (ja) 2003-06-17
AU1878201A (en) 2001-07-16
WO2001049309A2 (en) 2001-07-12
CO5271671A1 (es) 2003-04-30
GT200000224A (es) 2002-06-15

Similar Documents

Publication Publication Date Title
BR0014384A (pt) Compostos para o tratamento da isquémia
ES2176600T3 (es) Derivado de la propiofenona y procedimientos para su preparacion.
UY26635A1 (es) Métodos sinérgicos y composiciones para el tratamiento del cáncer
UY26724A1 (es) Métodos y composiciones para tratar el virus de la hepatitis c
AR020055A1 (es) Una composicion farmaceutica o cosmetica que contiene una sustancia de esmalte activa, usos de dicha composicion y un metodo para preparar la misma.
ES2145913T3 (es) Inhibidores de metaloproteasas.
MY130477A (en) Pharmaceutical compositions for the treatmen of mucositis, stomatitis and behcet,s syndrome
ATE218581T1 (de) Cyclosporinderivat, dessen herstellung und pharmazeutische zusammensetzung
HK1030880A1 (en) Matrix protein compositions for wound healing
DE69116380D1 (de) Pharmazeutische zubereitung zur behandlung verlängerter gerinnungszeit
BRPI0406796A (pt) Métodos para tratar hipertrofia prostática benigna, para reduzir um sintoma associado com a mesma, para reduzir o tamanho da próstata em um indivìduo humano e para profilaxia de bhp, composição farmacêutica oral de dose unitária, e, uso de lonidamina ou um análogo de lonidamina
UY26514A1 (es) " composición para el tratamiento de tejidos danados".
BR0010983A (pt) Preparações para a aplicação de agentes antiinflamatórios
ES2124983T3 (es) Utilizacion de un antagonista de substancia p para el tratamiento de las manchas rojas cutaneas de origen neurogeno.
ATE245444T1 (de) Pharmazeutische zusammensetzung, enthaltend peg- asparaginase, für die behandlung von hiv infektionen
GEP20043231B (en) Resorcinol Composition
RS50805B (sr) Upotreba fsh za lečenje neplodnosti
FI932654A0 (fi) Hydroxamsyraderivat, som hindrar lipoxigenas
BR0014751A (pt) Composto, estereoisÈmero ou mistura de estereoisÈmeros, composição farmacêutica, método de tratamento de um paciente em necessidade de tratamento antimicrobiano, e, uso de um composto
AR005730A1 (es) Forma de fanciclovir, procedimiento para prepararla, composiciones farmaceuticas que la contienen y metodo para el tratamiento o profilaxis deinfecciones virales y el uso de dicha forma -fanciclovir monoidrato.
ATE270110T1 (de) Arzneimittel enthaltend tissue inhibitor of metalloproteinases-2 (timp-2) als osteoanabol wirksame substanz
BR0308734A (pt) Composto, composição farmacêutica, uso do composto, e, método para prevenir ou tratar infecção
RU94044487A (ru) Применение 2-фенил-3-ароилбензотиофенов для лечения мужского бесплодия
BR0303384A (pt) Citalopram e seus usos no tratamento de pressão sanguìnea elevada
CO5040221A1 (es) Sal fumarato de (r)-5-(metilaminosulfonilmetil)-3-(n-metil- pilrrolidin-2-ilmetil)-1h-indol, composiciones farmaceuticas que contienen la misma y un procedimiento para preparar di- cha sal

Legal Events

Date Code Title Description
109 Application deemed to be withdrawn

Effective date: 20120529